{"name":"Viking Therapeutics","slug":"viking","ticker":"VKTX","exchange":"NASDAQ","domain":"vikingtherapeutics.com","description":"Viking Therapeutics is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders. The company's lead product candidates include VK2809, a thyroid hormone receptor beta agonist, and VK5211, a selective androgen receptor modulator. Viking Therapeutics is a relatively small player in the obesity/metabolic biotech sector, but its pipeline holds promise for addressing significant unmet medical needs.","hq":"San Diego, CA","founded":2014,"employees":"~75","ceo":"Brian Lian","sector":"Obesity / Metabolic Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"2.3B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":344955000,"netIncome":-359639000,"cash":165810000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"VK2809 patent cliff ($0.00 at risk)","drug":"VK2809","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"VK5211 patent cliff ($0.00 at risk)","drug":"VK5211","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"VK2735","genericName":"VK2735","slug":"vk2735","indication":"Obesity or overweight with weight-related comorbidities","status":"phase_3"}]}],"pipeline":[{"name":"VK2735","genericName":"VK2735","slug":"vk2735","phase":"phase_3","mechanism":"VK2735 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon signaling pathways to promote weight loss and improve metabolic parameters.","indications":["Obesity or overweight with weight-related comorbidities","Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Viking Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Viking Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting progress in its clinical pipeline and cash position.","drugName":"","sentiment":"neutral"},{"date":"2023-12-04","type":"deal","headline":"Viking Therapeutics Announces $20 Million Private Placement Financing","summary":"Viking Therapeutics announced a $20 million private placement financing to support its clinical development pipeline.","drugName":"","sentiment":"positive"},{"date":"2023-08-07","type":"trial","headline":"Viking Therapeutics Announces Positive Topline Results from Phase 2a Clinical Trial of VK2809","summary":"Viking Therapeutics announced positive topline results from its Phase 2a clinical trial of VK2809 in patients with non-alcoholic steatohepatitis (NASH).","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNYmtFNjdGWXBNbkxfbGpBYW53RXhvSlRkb3FoVG5KazFjWEY4RWZuMjVtYWtWWjdmTmNhSHBrSGZmTi01S3R1QWVOWmU3Y2xuVk52bEtJSDZiWlQ2TXFBYy1qRlhJV3JScmtaMzR6aldMbXdGdmNMdEVfTmNTVkx6ZGJQeEZ3c2JwV1llVTEzb2lBOHpwUkFXczZ6RFh3ZW5JeTdaMUVmajIyWHhCbmlnRmQxbmFqdGljOWlVTDN5aE85RlE2b0o3Nw?oc=5","date":"2026-04-02","type":"deal","source":"Stocktwits","summary":"VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits","headline":"VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxORjZvSjhNOWFQMWsxbUZsZHNwcEJ6bHRlM0pZcTZ0Y3p0dDlCam1zaEwxcHJBUlFaZl9ldlNhWjE2Nk52X285U3dGbXpuR0h6ZVVaMS1rOHhoWE9zYXBNbHZya0xUbnhseGZEbmJtTWVRZ19jM0tFYWhoZW9mQUplNTNsaEZ5Q2M1VG1tSnJNYUtEZTU3ZHp5Nk9CUTFYdWE3WG01SGIzQUdSOGNiZFlBSXVqaVJuQnJLV2xILXVFd0ZYbXN2WGQ1QmdKNUlYZTVlV0NZY0ZzNA?oc=5","date":"2026-03-24","type":"pipeline","source":"The Globe and Mail","summary":"Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail","headline":"Wall Street Analysts Are Bullish on Top Healthcare Picks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOeFdONUtIVzVhQlJ4dEs0Z2Rsd2ZGLUdaQ25HNmI0bEdCOW1XaFB0b0pOS2x4WHpBcEVTSUhGRnc2S0dNWkRfV1RrdzMxNzFaNHZ3UTJfMV9yNHdOZzR3cnd1bnk1dEV5RVN6eV9BSW9rWHNnbVRjeTRSYTBPbl85aW5CMEdDNWJzVFJGNUFJN0FYaGVtdHRPelNrZHJ5Sy1XWFBYMnJ6NGpxWlFXWjRpaE8xcllVY0s3?oc=5","date":"2026-02-26","type":"pipeline","source":"TradingView","summary":"Viking Therapeutics: The High-Stakes Weight Loss Contender - TradingView","headline":"Viking Therapeutics: The High-Stakes Weight Loss Contender","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPZEg5R2VpX2RFU09Ld2R1b28zc1VUNnR4RmlmMThnN1FZNWwyTDZ2bW0xeTU0MWtqaExkaHdienFkOUFJUk5wN1JBYWhKS0Q5SnhmMDhqX2luUC1lLXVCV1JRdTRwSWQ5S2NOOWdia1p6YkRfUzF5VEZKdExfSGRfQzFyRm5FLXFNTktiZnY0eWRqUQ?oc=5","date":"2026-02-23","type":"pipeline","source":"The Motley Fool","summary":"3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds - The Motley Fool","headline":"3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOd3ZzNzZXWnZ3Wkg2LVB3Y2MydlRSODBEZ2V3c1FlWXRQbGRqRkRHSXBtME1MZ0ZfcFM3RzJLYWRudm14WC1BaER0Vkw3TnpIbzM5QjkyNEtSa2ZOTENrVEZ4enlkbEtsUWFkU2MxcUgwTkNhUzZ0TUgyUFRuN3gxb1J6cw?oc=5","date":"2026-02-14","type":"pipeline","source":"Seeking Alpha","summary":"Viking Therapeutics: Full-Speed Ahead (NASDAQ:VKTX) - Seeking Alpha","headline":"Viking Therapeutics: Full-Speed Ahead (NASDAQ:VKTX)","sentiment":"neutral"},{"date":"2026-02-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNcTNJVmR1UXB2QTh2WENUWEtCcDhiYUhJQi1BSHI5YkIyV1lTem8xSURxa09mYVN3TGtvTVU5XzRxbjFCV2hqZnZjZGluUG5PWm9PWUhSc01EcVJfU1IyT0lnczZtMzlPdUdzejZpSE9MdXlSM2ZEVTljenNtR3JkVFVNZXMwNTFqOVBnY3U0YzF5UkhLc0xldQ?oc=5","date":"2026-01-26","type":"pipeline","source":"The Motley Fool","summary":"Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? - The Motley Fool","headline":"Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPekNBYXNTaEo5VVVQUXJSX0RLdUY4bHlLRUxIR1JyUmhjZUFwUXI5cDhqdzRfR0d6YXk3cE5ycWJQcTBaTXJCWWJMNEJ1NmxQYVRvOWE5cXYySUR1VmlJVFFMVHliME1qMHBKdWExVE42aUdBX0I4ZDBwalkyeE02T1F4NHlRbXQ1b3JhNTlWVWdHWHhiNEJaWTk0TE5ibDM4MnZsOElOV1RKcV9EbWI5UTR0c3hSbzB6dmttd3Y2ZHJmY1lkZjZCWjZOZndEb0JtYnZQZEJuRkVxQQ?oc=5","date":"2026-01-23","type":"pipeline","source":"FinancialContent","summary":"Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly - FinancialContent","headline":"Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPSlNNLUtqTWRiMzVNY1hLakxSaTRVYjdjelJyWU9iY0R6cnBJRTdSQ2JJTi1iMHBFNm4yeUlwYk8zN2JiRUUwMEE4OUY5MkxYYVllQ2pqdVV5cEp4UlhJeTZBLTQ0R1FFY2hodEY5SGVyeXhVbHVfWWVqRjBlRzVtczBTZURuWDcyTFZfRVc0N092THFSMS1ET1VRZS1Gc0FSdV9wX3hkdUZpRGZkNnc?oc=5","date":"2025-11-10","type":"pipeline","source":"TipRanks","summary":"Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. Next Big Pharma Target? - TipRanks","headline":"Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. Next Big Pharma Target?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxORFBleUVFcmpXcV9Xekx6dWdhcUZxLTdybVlwWnBQV1huc3lRSVZLNF9tMFp4TGhXZUdrZ1FubUhaMXoyTjFxckVjeUtzR1Q0YnM4SEg4ZDFCbmhTYnNOOEZwdlJycTJsVUJyZ2Itd1JoSElMTko2MzFqWDd5M0o0WXNhQUh6eE1LUGc4?oc=5","date":"2025-11-03","type":"deal","source":"Yahoo Finance","summary":"Viking Therapeutics Could Be Pharma’s Next Big Buyout Target - Yahoo Finance","headline":"Viking Therapeutics Could Be Pharma’s Next Big Buyout Target","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQMkYzUmhOZFN0RktudkVPa040ejBJOGJyeXFzMHBWVVA5N2hxY0diNjNVWE1fRE5oc3dfREFWUWM4Y09KZTV6dUJwUUJBVEpGMEFPMkY4MFFiRUdjUEJHQ2Y3aWdEUzJ4NjlfcDVlbG12a2pEN1dqSHp0cEVvanBwRThqb0gxNTZzdzhBV3BKQ1AtX0hMVEdlbA?oc=5","date":"2025-10-09","type":"pipeline","source":"The Motley Fool","summary":"Why Shares in Viking Therapeutics Surged This Week - The Motley Fool","headline":"Why Shares in Viking Therapeutics Surged This Week","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPQjhSQ0NsMlptc1FLU241Mk5tUGpfTWN1RldQY0JYdUp1X19TaEJiUjJpQWtwbnRFNy0ycldXb0JSMnR2MzR1ZmNlYU80YlRpQUNSeDhGeUp0TWtmdm9Lbi1Lbi1qMHQ2T1l5YUQ4MEJSd2dLOHlJWUl1S3hQS0VFTXo3R0k?oc=5","date":"2025-10-04","type":"deal","source":"Seeking Alpha","summary":"Viking Therapeutics Stock: A Speculative Buy (NASDAQ:VKTX) - Seeking Alpha","headline":"Viking Therapeutics Stock: A Speculative Buy (NASDAQ:VKTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNMEk0N0ItS0FCUzA2a1hvV2R1djlYU1lFY1RyeU5kQjdDbUtYVlN6T2xHMDNmYWxGY3ZEWlJiSk1CVEVCN0tqaWdPM1ZYNXdsck9iaG1vR0FPTnpPZjJ0WWhERWFhalJFb1p3eVd2MUhTV3pJNFVEZFppamxvYUFxMFdtXzgtZw?oc=5","date":"2025-09-16","type":"pipeline","source":"Yahoo Finance","summary":"Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Yahoo Finance","headline":"Viking Therapeutics, Inc. (VKTX): A Bull Case Theory","sentiment":"neutral"}],"patents":[{"drugName":"VK2809","drugSlug":"vk2809","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"VK5211","drugSlug":"vk5211","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Allergan","Novo Nordisk","Takeda"],"therapeuticFocus":["Metabolic Disorders","Endocrine Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":0,"period":"2017-12-31"},{"value":0,"period":"2016-12-31"},{"value":0,"period":"2015-12-31"},{"value":0,"period":"2014-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":344955000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-359639000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":165810000,"cashHistory":[],"totalAssets":715729000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}